Interesting future direction is also validation in RMS patients whether diminished PAX7 levels in PAX3-FOXO1 positive ARMS tumors may be associated with better prognosis and survival of the patients. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.